证券代码：301156 证券简称：美农生物 公告编号：2025-058 上海美农生物科技股份有限公司 关于控股股东、实际控制人的一致行动人 提前终止减持计划的公告 公司股东上海全裕智合管理咨询事务所（有限合伙）保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 3、股东减持股份情况 证券代码：301156 证券简称：美农生物 公告编号：2025-058 上海美农生物科技股份有限公司（以下简称"公司"）于 2025 年 7 月 23 日披露了《关于控股股东、实际控制人的一致行动人股份减持计划的预披露公告》 （公告编号：2025-048），上海全裕智合管理咨询事务所（有限合伙）（以下简 称"全裕"）持有公司股份 10,393,201 股，计划在减持计划公告披露之日起 15 个交易日后的 3 个月内以集中竞价方式减持其持有的公司股份不超过 1,407,846 股（即不超过公司总股本的 1%）。 公司近日收到股东全裕出具的《关于提前终止减持上海美农生物科技股份有 限公司股份的告知函》，截至本公告披露日，全裕通过集中竞 ...

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Meino Biological, including stock price movement and trading volume [1] - On October 13, Meino Biological's stock rose by 2.70%, with a trading volume of 253 million yuan, and a net financing purchase of 6.27 million yuan [1] - The total financing and securities balance for Meino Biological reached 54.91 million yuan, accounting for 3.39% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Meino Biological increased to 12,700, a rise of 74.14%, while the average circulating shares per person decreased by 33.43% [2] - For the first half of 2025, Meino Biological reported a revenue of 236 million yuan, representing a year-on-year growth of 13.69%, and a net profit attributable to shareholders of 23.53 million yuan, up 17.68% year-on-year [2] Group 3 - Since its A-share listing, Meino Biological has distributed a total of 154 million yuan in dividends [3] - As of June 30, 2025, the seventh largest circulating shareholder of Meino Biological is the Guotai Zhongzheng Livestock Breeding ETF, holding 821,400 shares as a new shareholder [3]

Group 1 - The pet economy concept stocks in the A-share market are experiencing a counter-trend rise, with notable increases in stock prices for several companies [1] - Yiyi Co., Ltd. reached a 10% limit up, while Babi Food increased by 6%, and other companies like Yuanfei Pet and Jieya Co. saw rises exceeding 5% [1] - The overall trend indicates a positive sentiment in the pet industry, as reflected by the MACD golden cross signal formation [1] Group 2 - Yiyi Co., Ltd. has a total market value of 6.346 billion and a year-to-date increase of 113.23% [2] - Babi Food has a market capitalization of 5.776 billion with a year-to-date increase of 45.81% [2] - Yuanfei Pet has a market value of 4.620 billion and a year-to-date increase of 54.05% [2] - Jieya Co. has a market capitalization of 3.847 billion and a year-to-date increase of 87.03% [2] - Petty Co. has a market value of 4.693 billion with a year-to-date increase of 8.49% [2] - Other companies like Biological Co. and Lusi Co. also showed significant increases in their stock prices and market values [2]

Group 1 - The A-share market's pet economy concept stocks are experiencing a counter-trend rise, indicating strong investor interest in this sector [1] - Yiyi Co., Ltd. has reached a 10% daily limit increase, showcasing significant market confidence [1] - Other notable performers include Babi Foods with a 6% increase, and Yuanfei Pet, Jeya Co., Ltd. with over 5% gains [1] Group 2 - Peti Co., Ltd., Bio Co., Ltd., Lusi Co., Ltd., and Shuangta Foods have all seen increases of over 4%, reflecting a broad positive sentiment in the pet industry [1] - Meino Biological, Haoyue Nursing, Ruipu Biological, and Chuangyuan Co., Ltd. have also reported gains exceeding 3%, further indicating the sector's resilience [1]

Core Insights - The company is currently focused on the research, production, and sales of feed additives and enzymatic protein feed raw materials, and is not involved in the development, production, or sales of vaccines [2] Group 1 - The company plans to continuously iterate and upgrade existing products based on industrial policies, industry development trends, and market and customer demands [2] - The company aims to develop efficient, safe, and environmentally friendly feed additives and enzymatic protein feed raw materials and their application solutions [2]

Core Viewpoint - The company, Meino Biological (301156.SZ), is currently focused on the research, production, and sales of feed additives and hydrolyzed protein feed materials, and does not plan to develop vaccines at this time [2]. Group 1: Company Focus - The company is concentrating on the development of feed additives and hydrolyzed protein feed materials [2]. - There is no current involvement in the research, production, or sales of vaccines [2]. - The company aims to continuously upgrade existing products based on industry policies, market trends, and customer needs [2]. Group 2: Future Development - The company is committed to researching and developing efficient, safe, and environmentally friendly feed additives and hydrolyzed protein feed materials and their application solutions [2].

Core Viewpoint - The company is currently focused on the research, production, and sales of feed additives and enzymatic protein feed raw materials, and is not involved in the research, production, or sales of vaccines [1] Group 1 - The company will continue to iterate and upgrade existing products based on industrial policies, industry development trends, market, and customer needs [1] - The company aims to develop efficient, safe, and environmentally friendly feed additives and enzymatic protein feed raw materials and their application solutions [1]

Core Viewpoint - The company aims to deepen its domestic market presence while expanding internationally, focusing on customer development and product innovation in the feed additive sector [1] Group 1: Market Strategy - The company will adhere to a market strategy of "deepening domestic and breaking through internationally" in the second half of the year [1] - In the domestic market, the company focuses on core customer development and implements the "expanding one product project" to optimize customer procurement costs and maximize customer value [1] - The overseas market strategy involves a "go out, invite in" approach, with increased resource investment to enhance international market development [1] Group 2: Product Development - The company continues to focus on the pig, dairy cow, and poultry markets while also expanding into aquaculture and beef and sheep markets [1] - There will be an increased investment in R&D to develop efficient, safe, and environmentally friendly feed additives and enzymatic protein feed raw materials [1] - The "annual production of 100,000 tons of corn protein deep processing project" is expected to be completed and enter trial production this year, which will introduce corn concentrated protein and corn enzymatic protein products to the market [1] Group 3: Industry Impact - The new project is expected to positively address the current shortage of domestic feed protein resources and provide new growth points for the company's business development [1]

Group 1: Report Basics - The report is about a research on Meinong Bio-tech, belonging to the agriculture, animal husbandry, feed, and fishery industry, with a research date of September 23, 2025 [1][16] - The listed company's reception staff includes the board secretary Zhang Weiwei and the head of the international marketing center, Hu Yanlingjun [16] Group 2: Research Institutions - The research institutions include securities companies such as Huatai Securities, Caitong Securities, Yuekai Securities, Huaxin Securities, and others like Hong Kong Dongjian International Securities, Xiaofeng Fund, and Fuzhijia Investment [17] - The proportion of securities companies among the research institutions is 46%, others 38%, law firms 8%, and investment companies 8% [20] Group 3: Core Views - The company adheres to the market strategy of "deeply cultivating the domestic market and breaking through the international market" and aims to become a globally leading animal nutrition technology company [23] - The company has a rich product line, a mature overseas dealer management model, and a set of core technologies, and it will continue to invest in international market development and new product R & D [23][27] Group 4: Company Business Analysis International Business - The company's international business has a first - mover advantage, with a sales network covering more than 40 countries and regions. It will continue to expand the international market through a two - pronged approach of "going out" and "digging deep" [23][25] - The overseas business income has maintained a growth rate of over 20% and accounts for nearly 40% of the total revenue. It adopts a sales model of "mainly distribution, supplemented by direct sales" [25] - The company has a mature overseas dealer management and selection model and manages exchange - rate risks through foreign exchange hedging [26] Core Technologies - The company has mastered core technologies such as formulation technology, preparation technology, and enzymatic hydrolysis technology, and continuously optimizes the process path design [27] Product Layout - The company's products include functional feed additives, nutritional feed additives, and enzymatic hydrolysis plant protein feed raw materials. It will launch corn - related products after the "100,000 - ton corn protein finishing project" is put into production [28][30] Talent Management - The company has built a "dual - wheel drive" talent management system of "internal self - cultivation and external talent introduction" and launched an equity incentive project and the "Meinong Academy" [30][31] Project Investment - The "100,000 - ton corn protein finishing project" is in line with national policies, which can improve the utilization rate of corn protein and create greater commercial value. Product prices will be determined by multiple factors [31][33][34]

每经头条（nbdtoutiao）——报价太低遭严防，投标企业还得"解释清楚"，一场国家组织的大型采购， 为何引发全行业关注 （记者 曾健辉） 每经AI快讯，美农生物发布公告称，2025年9月23日，美农生物接受华泰证券等投资者调研，公司董事 会秘书张维娓、国际营销中心负责人延凌郡参与接待，并回答了投资者提出的问题。 ...